Protocol for PTEN Expression by Immunohistochemistry in Formalin-fixed Paraffin-embedded Human Breast Carcinoma

被引：47

作者：

Sakr, Rita A. ^{[2
]}

Barbashina, Violetta ^{[3
]}

Morrogh, Mary ^{[2
]}

Chandarlapaty, Sarat ^{[4
]}

Andrade, Victor P. ^{[2
]}

Arroyo, Crispinita D. ^{[2
]}

Olvera, Narciso ^{[2
]}

King, Tari A. ^{[1
]}

机构：

[1] Mem Sloan Kettering Canc Ctr, Dept Surg, Breast Serv, New York, NY 10065 USA

[2] Mem Sloan Kettering Canc Ctr, Sloan Kettering Inst, New York, NY 10065 USA

[3] Mem Sloan Kettering Canc Ctr, Dept Pathol, New York, NY 10065 USA

[4] Mem Sloan Kettering Canc Ctr, Dept Med Oncol, New York, NY 10065 USA

来源：

APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY | 2010年 / 18卷 / 04期

关键词：

PTEN protein expression; immunohistochemistry; automated protocol; breast cancer; TUMOR-SUPPRESSOR GENE; REDUCED EXPRESSION; PROSTATE-CANCER; TRASTUZUMAB; RESISTANCE; PROTEIN; PATHWAY;

D O I：

10.1097/PAI.0b013e3181d50bd5

中图分类号：

R602 [外科病理学、解剖学]; R32 [人体形态学];

学科分类号：

100101 ;

摘要：

The PI3K/PTEN pathway plays a major role in carcinogenesis. Dysregulation of this pathway occurs frequently in breast cancer, and loss of PTEN expression is emerging as a potentially important mechanism of resistance to the widely used anti-HER2 therapy, trastuzumab. However, assays for loss of PTEN expression have suffered from lack of consistency. Here, we describe an automated and reliable protocol for PTEN protein expression by immunohistochemistry in formalin-fixed paraffin-embedded tissue that can be easily incorporated into clinical trials.

引用

页码：371 / 374

页数：4

共 12 条

[1] Reduced expression of PTEN correlates with breast cancer progression [J].

Bose, S ;

Crane, A ;

Hibshoosh, H ;

Mansukhani, M ;

Sandweis, L ;

Parsons, R .

HUMAN PATHOLOGY, 2002, 33 (04) :405-409

[2] Systems Biology Reveals New Strategies for Personalizing Cancer Medicine and Confirms the Role of PTEN in Resistance to Trastuzumab [J].

Faratian, Dana ;

Goltsov, Alexey ;

Lebedeva, Galina ;

Sorokin, Anatoly ;

Moodie, Stuart ;

Mullen, Peter ;

Kay, Charlene ;

Um, In Hwa ;

Langdon, Simon ;

Goryanin, Igor ;

Harrison, David J. .

CANCER RESEARCH, 2009, 69 (16) :6713-6720

[3] Promoter methylation of the PTEN gene is a common molecular change in breast cancer [J].

García, JM ;

Silva, J ;

Peña, C ;

Garcia, V ;

Rodríguez, R ;

Cruz, MA ;

Cantos, B ;

Provencio, M ;

España, P ;

Bonilla, F .

GENES CHROMOSOMES & CANCER, 2004, 41 (02) :117-124

[4] Loss of PTEN expression as a prognostic marker for tongue cancer [J].

Lee, JI ;

Soria, JC ;

Hassan, KA ;

El-Naggar, AK ;

Tang, XM ;

Liu, DD ;

Hong, WK ;

Mao, L .

ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 2001, 127 (12) :1441-1445

[5] PTEN, a putative protein tyrosine phosphatase gene mutated in human brain, breast, and prostate cancer [J].

Li, J ;

Yen, C ;

Liaw, D ;

Podsypanina, K ;

Bose, S ;

Wang, SI ;

Puc, J ;

Miliaresis, C ;

Rodgers, L ;

McCombie, R ;

Bigner, SH ;

Giovanella, BC ;

Ittmann, M ;

Tycko, B ;

Hibshoosh, H ;

Wigler, MH ;

Parsons, R .

SCIENCE, 1997, 275 (5308) :1943-1947

[6]

Nagata Y, 2004, CANCER CELL, V6, P117, DOI 10.1016/j.ccr.2004.06.022

[7] Human cancer, PTEN and the PI-3 kinase pathway [J].

Parsons, R .

SEMINARS IN CELL & DEVELOPMENTAL BIOLOGY, 2004, 15 (02) :171-176

[8] Immunohistochemical evidence of loss of PTEN expression in primary ductal adenocarcinomas of the breast [J].

Perren, A ;

Weng, LP ;

Boag, AH ;

Ziebold, U ;

Thakore, K ;

Dahia, PLM ;

Komminoth, P ;

Lees, JA ;

Mulligan, LM ;

Mutter, GL ;

Eng, C .

AMERICAN JOURNAL OF PATHOLOGY, 1999, 155 (04) :1253-1260

[9]

Rhei E, 1997, CANCER RES, V57, P3657

[10] Identification of a candidate tumour suppressor gene, MMAC1, at chromosome 10q23.3 that is mutated in multiple advanced cancers [J].

Steck, PA ;

Pershouse, MA ;

Jasser, SA ;

Yung, WKA ;

Lin, H ;

Ligon, AH ;

Langford, LA ;

Baumgard, ML ;

Hattier, T ;

Davis, T ;

Frye, C ;

Hu, R ;

Swedlund, B ;

Teng, DHF ;

Tavtigian, SV .

NATURE GENETICS, 1997, 15 (04) :356-362

← 1 2 →